We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.69%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$714M
AUM Growth
-$199M
Cap. Flow
+$8.81M
Cap. Flow %
1.23%
Top 10 Hldgs %
30.92%
Holding
97
New
3
Increased
39
Reduced
32
Closed
12

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$10.8M
2
ABBV icon
AbbVie
ABBV
+$10.2M
3
CVS icon
CVS Health
CVS
+$8M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.61M
5
UNH icon
UnitedHealth
UNH
+$6.05M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$10.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.1M
4
HUM icon
Humana
HUM
+$7.42M
5
BDX icon
Becton Dickinson
BDX
+$5.06M

Sector Composition

Rank Sector Weight
1 Healthcare 96.22%
2 Energy 0.06%
3 Technology 0.03%
4 Financials 0.02%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$422M
$2M 0.28%
38,000
-2,000
-5% -$134K
SAGE
77
DELISTED
Sage Therapeutics
SAGE
$1.44M 0.2%
50,000
– –
CLLS
78
Cellectis
CLLS
$291M
$1.33M 0.19%
144,604
– –
VKTX icon
79
Viking Therapeutics
VKTX
$3.94B
$936K 0.13%
200,000
– –
PVLA
80
Palvella Therapeutics
PVLA
$2.22B
$684K 0.1%
3,750
– –
IBM icon
81
IBM
IBM
$225B
$246K 0.03%
2,317
– –
CVX icon
82
Chevron
CVX
$386B
$215K 0.03%
2,974
– –
XOM icon
83
ExxonMobil
XOM
$657B
$205K 0.03%
5,388
+1,534
+40% +$84.7K
JHG
84
DELISTED
Janus Henderson
JHG
$163K 0.02%
10,645
– –
F icon
85
Ford
F
$55.7B
$141K 0.02%
29,164
– –
BUD icon
86
AB InBev
BUD
$159B
– –
-2,806
Closed -$230K
DIS icon
87
Walt Disney
DIS
$179B
– –
-2,083
Closed -$301K
GEN icon
88
Gen Digital
GEN
$17.4B
– –
-8,761
Closed -$224K
GOOGL icon
89
Alphabet (Google) Class A
GOOGL
$4.2T
– –
-3,200
Closed -$214K
HAL icon
90
Halliburton
HAL
$28.2B
– –
-8,299
Closed -$203K
JPM icon
91
JPMorgan Chase
JPM
$962B
– –
-2,095
Closed -$292K
QCOM icon
92
Qualcomm
QCOM
$171B
– –
-3,391
Closed -$299K
REGN icon
93
Regeneron Pharmaceuticals
REGN
$82.1B
– –
-27,000
Closed -$10.1M
RGNX icon
94
Regenxbio
RGNX
$703M
– –
-75,000
Closed -$3.07M
WFC icon
95
Wells Fargo
WFC
$264B
– –
-5,272
Closed -$284K
NSTG
96
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-140,000
Closed -$3.9M
DERM
97
DELISTED
Dermira, Inc.
DERM
– –
-800,000
Closed -$12.1M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rhenman & Partners Asset Management held 97 positions worth $714M, down 22% from $913M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2020 filing shows 3 new, 39 increased, 32 reduced and 12 closed positions. Its largest new stake was Zimmer Biomet: 82,400 shares worth $8.09M. The largest sale was Dermira, Inc., an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Energy and Technology.

  • Rhenman & Partners Asset Management's largest Q1 2020 buy was Zimmer Biomet: 82,400 shares worth $8.09M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q1 2020, an estimated $10.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $10.3M.
  • Rhenman & Partners Asset Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $12.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $714M portfolio in Q1 2020.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 12 in Q1 2020.
  • Rhenman & Partners Asset Management's portfolio value fell 22% quarter-over-quarter to $714M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2020, filed 16 Apr 2020.